We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The temporary pause was not prompted by drug-related adverse events in either the low- or high-dose adult arms of the phase 1 study, the company said. Read More
The trial will evaluate ProTcell’s ability to rapidly generate T cells in patients to reduce infections, Graft-versus-host disease and one-year non-relapse mortality. Read More
The pressure monitor, which comes with BlueTooth capabilities, delivers a continuous pressure microsensor directly into the patient’s muscle. Read More
The European Union approved Bavencio in January as a first-line maintenance treatment for adults with locally advanced or metastatic urothelial carcinoma who are progression-free after platinum-based chemotherapy. Read More
In a phase 3 study, Benlysta plus standard therapy improved kidney response rates and prevented worsening of kidney functions vs. standard therapy alone. Read More
The company is currently conducting a randomized, multicenter pivotal study for the device. The study, which began in May 2020, will continue at up to 25 U.S. sites. Read More